Trial Profile

ISIdE: Open Label, Multicentric, Single-arm Phase IIIB Trial to Evaluate the Safety and Efficacy of Sacituzumab Govitecan in Triple Negative Metastatic Breast Cancer Patients With a Biomarker Analysis

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 17 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sacituzumab govitecan (Primary)
Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Acronyms ISIdE

11 Jun 2025 Planned primary completion date changed from 1 Jun 2026 to 1 May 2026.
14 Jan 2025 Planned End Date changed from 1 May 2026 to 6 May 2028.
14 Jan 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Jun 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com